Healthcare

Share

Facebook Twitter Linkedin

Clarity Pharmaceuticals Ltd (ASX:CU6)

7.515 AUD

+0.025 0.334%

Last Updated at: 2024-09-13T01:00:00Z

Risk Disclaimer CU6 chart by TradingView

Back to ASX:CU6

Risk Disclaimer CU6 chart by TradingView

Sponsored Reports

Loading...

Previous Close (in AUD)	7.49
Change	+0.025 0.334%
52 W H/L (in AUD)	7.680/0.975
EBITDA (in AUD)	-44.648M
PE Ratio	--
Volume	147163
Diluted Eps TTM	-0.15

Total Assets (in AUD)	154.629M
Total Liabilities (in AUD)	8.332M
Revenue TTM (in AUD)	11.507M
Cash (in AUD)	136.506M
Market Cap (in AUD)	2,349.254 M
Revenue Per Share TTM	0.042
Gross Profit TTM (in AUD)	9.801M

Summary

---

Income Statement

Balance Sheet

Change in Cash

Operating Cash

Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.

National Innovation Centre, Sydney, NSW, Australia, 2015

61 2 9209 4037

https://www.claritypharmaceuticals.com

Employees: 50

Key Executives

Sr. No.	Name	Title	Year Born
1.	Dr. Alan John Taylor Ph.D.	Exec. Chairman	NA
2.	Dr. Colin David Biggin Ph.D.	MD, CEO & Exec. Director	NA
3.	Mr. David K. Green BEc., CA	Chief Financial Officer	NA
4.	Mr. Robert Vickery	Company Sec.	NA
5.	Dr. Michael D. Ironside	Director of Operations	NA
6.	Dr. Jeffrey Norenberg	Chief Scientific Officer	NA
7.	Dr. Ellen van Dam Ph.D.	Head of R&D	NA
8.	Mr. Shaemus Gleason	Exec. VP of US Operations	NA
9.	Dr. Robert M. Miller Ph.D.	Consultant Chief Medical Officer	1952
10.	Mr. William Cheadle	Financial Controller	NA

Peers

Sector: Healthcare

Industry: Biotechnology

Company	Change (AUD)	Price (AUD)	Trailing PE(x)	Forward PE(x)	Price Sales TTM(x)	Price to Book Value(x)	Enterprise Value to Revenue(x)	Enterprise Value to EBITDA(x)
CSL CSL Ltd	+0.180 0.060%	303.31	41.150	31.348	9.601	5.157	10.914	34.928
TLX Telix Pharmaceuticals Ltd	0.000 0.000%	19.04	983.000	21.008	8.466	28.693	8.215	177.654
NEU Neuren Pharmaceuticals Ltd	+0.215 1.580%	13.6	14.320	15.152	9.149	5.266	6.689	8.718
MSB Mesoblast Ltd	+0.015 1.596%	0.955	0.000	454.546	184.751	1.479	129.959	-9.862

• Income Statement
• Balance Sheet
• Cash Flow

Income Statement

(Currency in AUD)

Breakdown	30-06-2023	30-06-2022	30-06-2021	30-06-2020	30-06-2019
Income Before Tax	-24.499M	-23.737M	-10.221M	-6.954M	-
Minority Interest	-	-	-	-	-
Net Income	-24.602M	-23.755M	-10.221M	-6.954M	-
Selling General Administrative	4.705M	9.069M	3.819M	2.803M	-
Gross Profit	-	-	-	-	-
Reconciled Depreciation	0.101M	0.046M	-	-	-
Ebit	-26.364M	-30.291M	-10.313M	-7.057M	-3.766M
Ebitda	-36.064M	-30.245M	-	-	-
Depreciation And Amortization	-	0.046M	-	-	-
Operating Income	-24.499M	-30.291M	-10.221M	-6.948M	-
Other Operating Expenses	-	30.291M	-	-	0.782M
Interest Expense	-	0M	0M	0M	0M
Tax Provision	0.103M	0.018M	0M	0M	-
Interest Income	1.864M	0.095M	0M	0.006M	-
Net Interest Income	1.864M	0.095M	-	-	-
Income Tax Expense	0.103M	0.018M	-	-	-
Total Revenue	11.665M	6.554M	3.288M	2.898M	-
Total Operating Expenses	-	30.291M	-	-	-
Cost Of Revenue	-	-	-	-	-
Total Other Income Expense Net	9.801M	6.459M	-	-	-
Net Income From Continuing Ops	-24.602M	-23.755M	-	-	-
Net Income Applicable To Common Shares	-24.602M	-23.755M	-10.221M	-6.954M	-3.684M

Balance Sheet

(Currency in AUD)

Breakdown	30-06-2024	30-06-2023	30-06-2022	30-06-2021	30-06-2020
Total Assets	154.629M	76.896M	99.822M	22.613M	9.115M
Intangible Assets	-	-	-	-	-
Other Current Assets	4.921M	-	-	-	-
Total Liab	8.332M	7.721M	7.585M	2.335M	0.956M
Total Stockholder Equity	146.297M	69.176M	92.237M	20.278M	8.159M
Other Current Liab	6.005M	0.476M	4.656M	0.841M	0.412M
Common Stock	249.447M	132.82M	132.115M	44.904M	23.933M
Capital Stock	-	132.82M	132.115M	-	-
Retained Earnings	-112.699M	-70.374M	-45.796M	-28.85M	-18.866M
Good Will	-	-	-	-	-
Other Assets	-	0.012M	0.012M	0.011M	0.011M
Cash	136.506M	5.975M	55.336M	8.439M	5.265M
Cash And Equivalents	-	25.238M	25M	-	-
Total Current Liabilities	8.089M	7.542M	7.506M	2.251M	0.947M
Current Deferred Revenue	-	-	-	-	-
Net Debt	-136.506M	-	-55.336M	-	-
Short Term Debt	-	0M	0M	0M	0M
Short Long Term Debt	-	-	-	-	-
Short Long Term Debt Total	-	-	-	-	-
Other Stockholder Equity	-	6.73M	5.917M	4.224M	3.092M
Property Plant Equipment	-	0.206M	0.26M	0.093M	0.05M
Total Current Assets	154.061M	76.678M	99.55M	22.508M	9.054M
Long Term Investments	-	0.012M	0.012M	-	-
Short Term Investments	-	33.802M	37M	10.5M	1M
Net Receivables	12.635M	10.002M	6.658M	3.372M	2.66M
Long Term Debt	-	-	-	-	-
Inventory	-	-	-	-	-
Accounts Payable	2.084M	2.847M	2.85M	0.228M	0.156M
Accumulated Other Comprehensive Income	9.549M	-	5.917M	-	-
Non Currrent Assets Other	0.013M	-	-	-	-
Non Current Assets Total	0.568M	0.218M	0.272M	-	-
Capital Lease Obligations	-	-	-	-	-
Long Term Debt Total	-	0M	0M	0M	0M

Cash Flow

(Currency in AUD)

Breakdown	30-06-2023	30-06-2022	30-06-2021	30-06-2020	30-06-2019
Investments	3.198M	-26.5M	-9.5M	-9.5M	-9.5M
Total Cashflows From Investing Activities	3.151M	-26.714M	-9.56M	-0.014M	-0.016M
Total Cash From Financing Activities	0.232M	86.928M	20.414M	8.219M	5.927M
Net Income	-24.602M	-23.755M	-10.221M	-6.954M	-3.684M
Change In Cash	-24.123M	46.897M	3.174M	1.375M	2.213M
Begin Period Cash Flow	55.336M	8.439M	-	-	-
End Period Cash Flow	31.213M	55.336M	8.439M	-	-
Total Cash From Operating Activities	-27.5M	-13.314M	-7.677M	-6.83M	-3.707M
Depreciation	0.101M	0.046M	0.016M	0.017M	0.022M
Other Cashflows From Investing Activities	3.198M	-26.5M	-9.5M	-	-
Dividends Paid	-	-	-	-	-
Change To Inventory	-	-	-	-	-
Sale Purchase Of Stock	0.244M	-5.603M	21.096M	4.697M	-
Other Cashflows From Financing Activities	-0.013M	0.132M	-0.681M	3.514M	-4.523M
Capital Expenditures	0.047M	0.213M	0.06M	0.014M	0.016M
Change In Working Capital	8.307M	3.338M	2.562M	2.012M	-
Other Non Cash Items	-	-	-	-	-
Free Cash Flow	-27.547M	-0.213M	-	-	-

No data found

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

• Top Gainer
• Top Loser